Cancer Control最新文献

{"title":"Persistent Health Inequalities in the Burden of Gastrointestinal Cancers Among the Elderly From 1990 to 2021: A Population-Based Study.","authors":"Zijian Qiu, Shengjian Yu, Ying Lou, Xiaofeng Ma, Feng Xuan","doi":"10.1177/10732748251330693","DOIUrl":"10.1177/10732748251330693","url":null,"abstract":"<p><p>IntroductionGlobally, aging populations highlight gastrointestinal cancers as a major public health concern. Our study aimed to quantify the trends and inequalities in the burden of gastrointestinal cancers among the elderly from 1990 to 2021.MethodsUtilizing the 2021 Global Burden of Diseases (GBD) database, our secondary analysis targeted disability-adjusted life-years (DALYs) for gastrointestinal cancers among the elderly (60+). DALYs are a composite indicator of health loss, calculated as the sum of years of life lost due to premature mortality and years lived with disability. The age-standardized DALYs rate (ASDR) was calculated using the direct standardization method. Trends were quantified by estimated annual percentage change in ASDR. The Slope index of inequality (SII) and concentration index were employed to quantify absolute and relative health inequalities.ResultsIn 2021, colon and rectum cancer (CRC) had the highest global ASDR among the elderly, followed by stomach cancer (SC), esophageal cancer (EC), pancreatic cancer (PC), liver cancer (LC), and gallbladder and biliary tract cancer (GBTC). Between 1990 and 2021, ASDR for gastrointestinal cancers decreased globally, except for PC. Health inequalities exhibited varied patterns: EC showed a worsening inequality among lower SDI countries in SII, while SC experienced a shift to higher burden among lower SDI countries in SII. LC displayed an improving inequality among lower SDI countries in SII. The concentration index for EC, SC, and LC demonstrated a transition towards higher SDI countries. CRC, GBTC, and PC maintained a higher burden in higher SDI countries, while the SII and concentration index reflected improvements in inequality.ConclusionFrom 1990 to 2021, a substantial decline was observed in the burden of gastrointestinal cancers, except for PC. Persistent and evolving health inequalities highlight the need for comprehensive, multi-level interventions to reduce disparities and achieve equitable health outcomes for all.</p>","PeriodicalId":49093,"journal":{"name":"Cancer Control","volume":"32 ","pages":"10732748251330693"},"PeriodicalIF":2.5,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11970069/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143781833","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Whole-Brain Radiotherapy Simultaneous Integrated Boost Intensity-Modulated Radiotherapy Combined With Anlotinib in the Treatment of Brain Metastases.","authors":"Wei Tao, Chunyu Jiang, Jiaqi Xie, Wei Liu, Shuan Wang, Jianyu Zhang, Xue Qiao, Jingyi Yu, Ting Jia, Yuandong Cao","doi":"10.1177/10732748251319489","DOIUrl":"10.1177/10732748251319489","url":null,"abstract":"<p><strong>Introduction: </strong>Whole-brain radiotherapy simultaneous integrated boost intensity-modulated radiotherapy (WBRT + SIB-IMRT) is a potential treatment approach for brain metastasis (BM) that may result in improved overall survival (OS). However, the safety and efficacy of WBRT + SIB-IMRT combined with anlotinib for BM treatment remain uncertain.</p><p><strong>Methods: </strong>We retrospectively compared the safety and efficacy of anlotinib + WBRT + SIB-IMRT with those of WBRT + SIB-IMRT in patients with BM from 2019 to 2022. The adverse reaction type and grade, intracranial objective response rate (iORR), intracranial disease control rate (iDCR), OS, and intracranial progression-free survival (iPFS) of anlotinib + WBRT + SIB-IMRT were compared with those of WBRT + SIB-IMRT alone.</p><p><strong>Results: </strong>In total, 63 patients received either anlotinib + WBRT + SIB-IMRT or WBRT + SIB-IMRT alone (n = 31 and 32, respectively). No significant clinical differences were found between the two groups. The iORR and iDCR were higher in the anlotinib + WBRT + SIB-IMRT group than in the WBRT + SIB-IMRT group. The median iPFS and median OS of the 31 patients who received anlotinib + WBRT + SIB-IMRT were 14.5 and 18.9 months, respectively, whereas the median iPFS and median OS for the 32 patients who received WBRT + SIB-IMRT alone were 11.4 and 14.9 months, respectively. Thus, anlotinib combined with WBRT + SIB-IMRT increased the duration of iPFS, but not OS. iPFS was influenced by the Karnofsky Performance Status (KPS) score, age, extracranial distant metastasis, and addition of anlotinib to treatment, whereas OS correlated with age, extracranial distant metastasis, and KPS score. No treatment-related adverse events of grade 3 or higher occurred in either group.</p><p><strong>Conclusions: </strong>Anlotinib combined with WBRT + SIB-IMRT is effective for BM and is well tolerated by patients.</p>","PeriodicalId":49093,"journal":{"name":"Cancer Control","volume":"32 ","pages":"10732748251319489"},"PeriodicalIF":2.5,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11829290/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143416751","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Evolving Dynamics of Colorectal Cancer in High Socio-Demographic Regions.","authors":"Laalithya Konduru, Simranjeet Singh Dahia, Claudia Szabo, Savio G Barreto","doi":"10.1177/10732748251321672","DOIUrl":"10.1177/10732748251321672","url":null,"abstract":"<p><strong>Background: </strong>Colorectal cancer (CRC) poses a significant global health challenge, with evolving demographic trends emphasizing the need for accurate forecasting models. Existing forecasting models lack comprehensive coverage. By integrating machine learning algorithms, this study aims to provide more accurate and precise predictions, filling critical gaps in understanding CRC incidence, death, and disability-adjusted life year (DALY) rate trends, especially in high socio-demographic index (SDI) regions. Specific emphasis is placed on exploring age-, sex-, and country-specific variations in CRC trends.</p><p><strong>Materials and methods: </strong>An ensemble forecasting algorithm integrating Simple Linear Regression, Exponential Smoothing, and Autoregressive Integrated Moving Average, capable of handling a short time series was developed and validated, utilizing a dataset encompassing age-, sex-, and country-specific CRC incidence, mortality, and DALY rates.</p><p><strong>Results: </strong>Our forecasting models reveal rising trends in CRC burden in the 15-49 years age group (young-onset) and decreasing trends in CRC burden in the 50-74 years age group (late-onset) in high SDI regions with sex-specific variations in incidence, mortality, and DALY rates. Some inflection points for demographic shifts in CRC disease burden, particularly death rates, were identified as early as within the next 5 years. We predict a shift in CRC burden towards females, particularly in older adults.</p><p><strong>Conclusion: </strong>A novel multifactor model was developed for comparing the incidence, mortality, and DALY rates of young- and late-onset CRC in high SDI regions. The rising incidence of young-onset CRC in high SDI regions underscores the need for proactive health strategies. By refining predictive models, adjusting screening guidelines to target younger, high-risk populations, and investing in public awareness and research, we can facilitate early detection and improve outcomes. This study addresses a significant gap in CRC forecasting and provides a robust framework for anticipating demographic shifts in CRC burden, making it an indispensable tool for healthcare planning.</p>","PeriodicalId":49093,"journal":{"name":"Cancer Control","volume":"32 ","pages":"10732748251321672"},"PeriodicalIF":2.5,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11833813/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143442514","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Can the Use of Artificial Intelligence-Generated Content Bridge the Cancer Knowledge Gap? A Longitudinal Study With Health Self-Efficacy as a Mediator and Educational Level as a Moderator.","authors":"Zehang Xie, Ru Chen, Wenjuan Ding","doi":"10.1177/10732748251319487","DOIUrl":"10.1177/10732748251319487","url":null,"abstract":"<p><strong>Objectives: </strong>The cancer knowledge gap represents a significant disparity in awareness and understanding of cancer-related information across different demographic groups. Leveraging Artificial Intelligence-Generated Content (AIGC) offers a promising approach to personalize health education and potentially bridge this gap. This study aimed to evaluate the potential of AIGC to bridge the cancer knowledge gap, assessing the roles of health self-efficacy as a mediator and educational level as a moderator in this relationship.</p><p><strong>Methods: </strong>A 6-month longitudinal study was conducted using online surveys distributed to undergraduate students in non-medical disciplines at one university and graduate students in medical specialties at another university in China. The study assessed the frequency of AIGC use, health self-efficacy, and cancer knowledge at two time points.</p><p><strong>Results: </strong>The results indicated that AIGC use significantly enhanced cancer knowledge levels and health self-efficacy over time. Educational level notably moderated the effects of AIGC use, with non-medical undergraduate students showing greater gains in knowledge and self-efficacy. Additionally, health self-efficacy mediated the relationship between AIGC use and cancer knowledge, underscoring the importance of health self-efficacy. The study confirms the efficacy of AIGC in narrowing the cancer knowledge gap and enhancing health self-efficacy, particularly among students with lower initial medical knowledge.</p><p><strong>Conclusion: </strong>These findings highlight the potential of integrating AIGC tools in cancer education and public health interventions, particularly for individuals at different educational levels. By tailoring digital health resources to varying educational needs, these interventions could enhance cancer knowledge acquisition, improve health self-efficacy, and contribute to better cancer prevention and control outcomes.</p>","PeriodicalId":49093,"journal":{"name":"Cancer Control","volume":"32 ","pages":"10732748251319487"},"PeriodicalIF":2.5,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11811976/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143392226","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A Retrospective Observational Study on the Impact of Digital Strategies to Boost Cervical Screening Uptake in Primary Care.","authors":"Lisa Haith, Carl Deaney, Danielle Reesby, Victoria Ellis, Georgia Cole, Victoria Scott, Alena Nicholson, Rachael Hemingway-Deaney","doi":"10.1177/10732748251330705","DOIUrl":"https://doi.org/10.1177/10732748251330705","url":null,"abstract":"<p><p>IntroductionCervical cancer is largely preventable through regular screening, yet uptake in the UK remains below national targets, particularly among harder-to-reach groups. Despite national efforts, barriers such as fear, embarrassment, and low health literacy continue to hinder participation. This retrospective study evaluates the impact of delivering information and education regarding cervical screening (CS) to hard-to-reach populations, with the aim of increasing CS uptake in line with the national target of 80% coverage.MethodsUsing a multidisciplinary team approach, women who had previously missed screenings were identified through electronic records. Remote interventions, including educational videos delivered via email and SMS, and an online booking system, were implemented to provide accessible information and flexible appointment options. These interventions aimed to address common barriers and encourage informed participation.ResultsOver 3 months, screening rates increased significantly. Uptake among women aged 25-49 rose from 77% to 80.5%, while rates among women aged 50-64 improved from 81% to 97%.ConclusionThis study highlights the potential effectiveness of remote communication tools in increasing cervical screening participation, particularly among populations historically less likely to engage. Integrating digital resources into routine practice also has the potential to reduce administrative burdens, improve patient education, and make screening more accessible. By addressing key barriers and providing flexible booking options, primary care clinics can enhance screening uptake, supporting earlier cervical cancer detection and ultimately improving patient outcomes.</p>","PeriodicalId":49093,"journal":{"name":"Cancer Control","volume":"32 ","pages":"10732748251330705"},"PeriodicalIF":2.5,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143788956","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Moderate Hypofractionated Post-Prostatectomy Radiotherapy (MYSTERY) Versus Conventionally Fractionated Post-Prostatectomy Radiotherapy (COPORT) for the Patients With Localized Prostate Cancer: The Protocol of a Prospective, Randomized Trial.","authors":"Yiyin Liang, Weiwei Zhang, Xianzhi Zhao, Huojun Zhang","doi":"10.1177/10732748251317682","DOIUrl":"10.1177/10732748251317682","url":null,"abstract":"<p><strong>Introduction: </strong>A few studies have examined whether the safety and efficacy of moderate hypofractionated post-prostatectomy radiotherapy (moderate HYPORT, also called MYSTERY) are equal to those of conventionally fractionated post-prostatectomy radiotherapy (COPORT) in patients with localized prostate cancer. Therefore, this study aims to compare the safety and efficacy of MYSTERY and COPORT in patients with postoperative prostate cancer.</p><p><strong>Methods and analysis: </strong>This study is a prospective, single-center, open-label, randomized controlled clinical trial. Patients with localized prostate cancer will be randomly allocated to receive COPORT (66-74 Gy at 2 Gy per fraction) or MYSTERY (57.5-65 Gy at 2.5 Gy per fraction). The primary outcomes are radiotherapy-related gastrointestinal and genitourinary adverse events. Secondary outcomes include progression-free survival, quality of life, medical expenses, and overall survival.</p>","PeriodicalId":49093,"journal":{"name":"Cancer Control","volume":"32 ","pages":"10732748251317682"},"PeriodicalIF":2.5,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11815805/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143400432","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Long-Term Outcomes of Patients Diagnosed With Sacral Chordoma in a Retrospective Multicenter Study.","authors":"Aneta Maria Borkowska, Andrzej Pieńkowski, Paulina Chmiel, Tomasz Skóra, Radosław Michalik, Piotr Rutkowski, Mateusz Jacek Spałek","doi":"10.1177/10732748251323730","DOIUrl":"10.1177/10732748251323730","url":null,"abstract":"<p><p>BackgroundChordoma is a rare and aggressive primary bone sarcoma. En-block resection remains the primary treatment, but some patients are unable to undergo it due to the location and potential complications. Currently, there is no direct comparison of the effects of radiotherapy (RTH) and surgical treatment. However, retrospective analyses indicate the potential benefits of using RTH.MethodsA retrospective analysis was conducted on 48 patients with sacral chordoma who were treated with surgery and/or radiotherapy between 2001-2020. Among those, 22 were initially treated with surgery, 19 with definitive radiotherapy, and 7 received combined treatment. The outcomes of the treatment of recurrence in 16 patients were considered. The resection margins were defined according to R classification, and the Kaplan-Meier method was employed to calculate disease-free survival (DFS) and overall survival (OS).ResultsThe median (mOS) for the entire cohort was 80.6 months (95% CI: 62.3-NA), and the median (mDFS) was 40.4 months (95% CI: 35-69.5). Patients who underwent radical surgery of the primary tumor did not achieve the mOS (mean 68), while patients treated only with RTH for the primary tumor achieved an mOS of 62.3 months (95% CI: 52.1-NA). This resulted in a significant advantage of surgery over RTH in terms of OS (<i>P</i> = 0.01). This was not observed for DFS. The 3-year DFS rates were 65% in the surgical treatment group and 53.3% in the RTH group. The 3-year OS rates were 96% in the surgery group and 88.9% in the RTH group. In the treatment of recurrence, there were no statistically significant differences between RTH and surgery, for OS (<i>P</i> = 0.76).ConclusionsRadical surgery remains the optimal treatment for sacral chordoma. For patients who are not candidates for surgical intervention, RTH offers excellent long-term outcomes. The treatment of recurrence remains a significant challenge. Comparing modern RTH techniques and surgical procedures could provide further insights.</p>","PeriodicalId":49093,"journal":{"name":"Cancer Control","volume":"32 ","pages":"10732748251323730"},"PeriodicalIF":2.5,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11898242/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143606811","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Quality of Life and Associated Factors Among Family/Caregivers of Pediatric Patients Treated for Cancer at Tikur Anbessa Specialized Hospital: Institution-Based Cross-Sectional Study.","authors":"Zenebe Negash, Eden M Kinfe, Urji Zerihun, Atalay M Fentie","doi":"10.1177/10732748251320821","DOIUrl":"10.1177/10732748251320821","url":null,"abstract":"<p><strong>Background: </strong>Pediatric cancer significantly affects the quality of life (QOL) of patients and their families/caregivers particularly in low-income countries where there is scarcity of resources. Thus, the purpose of this study was to evaluate the QOL and associated factors among family/caregivers of pediatric patients treated for cancer at Tikur Anbassa Specialized Hospital (TASH), Addis Ababa, Ethiopia.</p><p><strong>Method: </strong>An institution-based cross-sectional study design was used to collect information from family/caregivers who were present in the pediatric oncology unit at TASH from January 2, 2023 to May 30, 2023. The validated Amharic version of the caregiver oncology quality of life questionnaire (CarGOQOL) was used to collect the data. A random sampling technique was applied to select the study participants. The descriptive and regression analysis were conducted using statistical software SPSS version 27.0.</p><p><strong>Results: </strong>A total of 350 family/caregivers answered the questionnaire. The overall response rate was 82.7%, and about 55% of the respondents were women. Among the participants, under-35 age made up the majority (60.9%). About 81% of family/caregivers were parents, and 77.7% of family/caregivers were married. More than half of the participants have at least a secondary level education. In addition, about two-thirds of the participants (63%) live in rural areas. Furthermore, more than half of the participants generate less than $17.86 per month. Nearly fifty percent of family/caregivers of pediatric cancer patients had poor QOL. The finding showed that widowed family/caregivers (AOR:5.59, 95%CI: 1.12, 27.79, <i>P</i>-value: 0.03) had poor QOL as compared to married, and those with a monthly income of between $17.87- $89.29 were less likely to have poor QOL compared to those with an income below <$17.87 (<i>P</i>-value: 0.01).</p><p><strong>Conclusion: </strong>In the current study, poor QOL was high among family/caregivers of pediatric cancer patients. Being widowed and lowest income were significantly associated with the QOL of the caregivers of pediatric patients with cancer.</p>","PeriodicalId":49093,"journal":{"name":"Cancer Control","volume":"32 ","pages":"10732748251320821"},"PeriodicalIF":2.5,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11815790/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143400434","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Research Status of Clustered Regulary Interspaced Short Palindromic Repeats Technology in the Treatment of Human Papillomavirus (HPV) Infection Related Diseases.","authors":"Minxue Tang","doi":"10.1177/10732748241300654","DOIUrl":"10.1177/10732748241300654","url":null,"abstract":"<p><p><b>Background:</b> CRISPR/Cas9 technology has rapidly advanced as a pivotal tool in cancer research, particularly in the precision targeting required for both detecting and treating malignancies. Its high specificity and low off-target effects make it exceptionally effective in applications involving Human Papillomavirus (HPV) related diseases, most notably cervical cancer. This approach offers a refined methodology for the rapid detection of viral infections and provides a robust platform for the safe and effective treatment of diseases associated with viral infections through gene therapy.<b>Purpose:</b> Gene therapy, within this context, involves the strategic delivery of genetic material into target cells via a vector. This is followed by the meticulous modulation of gene expression, whether through correction, addition, or suppression, specifically honed to target tumor cells while sparing healthy cells. This dual capacity to diagnose and treat at such a precise level underscores the transformative potential of CRISPR/Cas9 in contemporary medical science, particularly in oncology and virology.<b>Research Design:</b> This article provides an overview of the advancements made in utilizing the CRISPR-Cas9 system as a research tool for HPV-related treatments while summarizing its application status in basic research, diagnosis, and treatment of HPV.<b>Data Collection:</b> Furthermore, it discusses the future prospects for this technology within emerging areas of HPV research and precision medicine in clinical practice, while highlighting technical challenges and potential directions for future development.</p>","PeriodicalId":49093,"journal":{"name":"Cancer Control","volume":"32 ","pages":"10732748241300654"},"PeriodicalIF":2.5,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11748153/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143014677","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clinicopathological Features and Prognoses of Patients With Splenic Metastases From Breast Cancer: A Single-Centre, Retrospective Study.","authors":"Xiaofeng Xie, Mingrui Ma, Xue Bai, Jing Hu, Haijie Zheng, Xiongqi Guo, Jiayi Huang, Xuelian Chen, Liping Chen, Xiaofeng Lan, Lin Song, Caiwen Du","doi":"10.1177/10732748241310578","DOIUrl":"10.1177/10732748241310578","url":null,"abstract":"<p><strong>Purpose: </strong>Splenic metastases (SM) from breast cancer (SMBC) are exceedingly rare. To date, the relevant literature is primarily based on pan-tumour species, with only a few studies exploring SM specifically in relation to breast cancer. As such, the present retrospective study explored the clinicopathological characteristics and prognoses of patients with SMBC at the breast care centre of the authors' hospital.</p><p><strong>Methods: </strong>Data from patients newly diagnosed with metastatic breast cancer (MBC) between June 2017 and June 2022 were extracted from medical records at the authors' hospital. Clinicopathological characteristics and their associations with progression-free survival (PFS [time from diagnosis of initial recurrence and/or metastasis to diagnosis of SM]), first overall survival (^1stOS [time from diagnosis of breast cancer to death or last follow-up visit]), and second overall survival (^2ndOS [time from diagnosis of SM to death or last follow-up visit]) were analysed in patients with SMBC.</p><p><strong>Results: </strong>In total, 1009 patients with MBC were identified, of whom 18 (1.7%) had SM. T1 and T2 stages were documented in 15 (83.3%) patients, whereas N2 and N3 were documented in 13 (62.2%). 14 (77.8%) patients were oestrogen receptor and/or progesterone receptor positive. A Ki-67 index ≥ 30% accounted for 72.2% (13/18) of cases, and all patients were histological grade II or III. Liver and/or lung metastases were documented in all 18 (100%) patients. Median PFS was 6.3 months. The median ^1stOS and ^2ndOS were 41.8 and 10.6 months, respectively. The number of previous treatment lines before diagnosis of SM was a significant adverse prognostic factor for PFS, and disease-free survival was a significant adverse prognostic factor for ^1stOS.</p><p><strong>Conclusion: </strong>SMBC commonly presents with diffuse multiple organ metastases in the terminal stage of malignancy and has a poor prognosis, which may provide deeper insight into SMBC for clinicians.</p>","PeriodicalId":49093,"journal":{"name":"Cancer Control","volume":"32 ","pages":"10732748241310578"},"PeriodicalIF":2.5,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142927396","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}